| Gene symbol | CD79B | Synonyms | AGM6, B29, IGB, Igbeta | Type of gene | protein-coding |
| Chromosome | 17 | Map location | 17q23.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | CD79b molecule | ||||
| GTO ID | GTC3370 |
| Trial ID | NCT05773040 |
| Disease | Lymphoma | B-Cell Lymphoma |
| Altered gene | CD79b |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | JV-213 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas |
| Year | 2023 |
| Country | United States |
| Company sponsor | M.D. Anderson Cancer Center |
| Other ID(s) | 2022-0938|NCI-2023-02055 |
| Cohort 1 | |||||||||||
|
|||||||||||